PMC6557967_01
(A) Development of coagulation factors and platelets during treatment: VWF:Act, von Willebrand factor activity; VIII:C, factor VIII activity; IVIg, immunoglobulin; ASCT, d0 of consolidation therapy: autologous stem cell transplantation; (B) recovery of VWF:Ag, VWF:Act and VIII:C after administration of 92 units/kg bodyweight Haemate P (plasma-derived VWF / FVIII concentrate)
IJHOSCR-13-7-g001.jpg
PMC6557967_01_IJHOSCR-13-7-g001.jpg
F1
We administered an initial dose of 6000 units (92 units/kg bodyweight) of Haemate P, but low concurrent recovery values with less than 10% VWF: Act three hours after VWF administration (see Figure 1B) indicated a rapid clearance of VWF. IVIg) to maintain normal VWF levels throughout the consolidation therapy (Figure 1A). Impairment of platelet aggregation, however, was not ameliorated by IVIg administration.  An immediate and sustainable rise of VWF and FVIII after ASCT was documented (Figure 1A).